KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Leases (2019 - 2025)

Historic Leases for Halozyme Therapeutics (HALO) over the last 8 years, with Q4 2025 value amounting to $37.7 million.

  • Halozyme Therapeutics' Leases rose 1031.28% to $37.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $37.7 million, marking a year-over-year increase of 1031.28%. This contributed to the annual value of $37.7 million for FY2025, which is 1031.28% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Leases stood at $37.7 million for Q4 2025, which was up 1031.28% from $30.8 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Leases high stood at $40.5 million for Q4 2022, and its period low was $1.6 million during Q1 2022.
  • Over the past 5 years, Halozyme Therapeutics' median Leases value was $33.4 million (recorded in 2024), while the average stood at $24.4 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Leases tumbled by 4927.3% in 2022 and then skyrocketed by 241082.8% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Leases stood at $2.0 million in 2021, then soared by 1920.42% to $40.5 million in 2022, then decreased by 8.98% to $36.8 million in 2023, then fell by 7.23% to $34.2 million in 2024, then increased by 10.31% to $37.7 million in 2025.
  • Its last three reported values are $37.7 million in Q4 2025, $30.8 million for Q3 2025, and $31.9 million during Q2 2025.